COLLPLANT BIOTECHNOLOGIES LT
CLGNNASDAQ🏆 #3711 by market capEarnings Aug 18US Equity
$0.30▼ $0.01 (−2.41%)
Live1h—
24h▼ 2.4%
7d▼ 3.8%
14d▼ 4.3%
30d▼ 18.9%
1y▼ 89.9%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-84.3%
Declining
📊Gross Margin
-147.6%
Thin
💵FCF Margin
—
⚖️P/S Ratio
15.8x
Expensive
Otter Score
43
Weak
Trading Snapshot
- Day Range
- $0.30 – $0.30
- 52-Week Range
- $0.27 – $3.23
- Volume
- $2.23B
- Avg Volume
- $2.21B
- Shares Outstanding
- 18.9M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $389,000
- Last Q Revenue
- $93,464
- P/E Ratio
- —
- P/S Ratio
- 15.8x
- EPS (TTM)
- $-1.03
- Dividend Yield
- —
Why Investors Own CLGN
- ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$389,000▲ +19.5% YoY
Gross Margin (TTM)
31.6%▲ +3.7% YoY
Operating Income (TTM)
$84,024▲ +19.5% YoY
Free Cash Flow (TTM)
$94,916▲ +19.5% YoY
About COLLPLANT BIOTECHNOLOGIES LT
A company profile for COLLPLANT BIOTECHNOLOGIES LT isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
43/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
Latest News & Updates
🚀
Reuters·2h ago
COLLPLANT BIOTECHNOLOGIES LT tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift CLGN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
COLLPLANT BIOTECHNOLOGIES LT announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.